Результаты поиска

Health management program: factors influencing completion of therapy with high-dose interferon alfa-2b for high-risk melanoma.

The goal of the 1-year observational, multicentre, open-label study reported here was to identify factors influencing adherence to high-dose interferon alfa-2b adjuvant therapy in patients at high risk of recurrence following surgical excision of malignant melanoma. The study was carried out in 23 tertiary-care centres across Canada.The 225 patients enrolled in the study all had malignant melanoma that was surgically excised and that required adjuvant treatment with interferon alfa-2b. Of these patients, 64% were men. Mean age was 51.7 years. All patients received interferon alfa-2b treatment

Совпадение в полном тексте источника
… Most of the patients came from the Canadian provinces of Ontario (48%), Alberta (18%), Quebec (11.0%), and British Columbia (10%). All subjects were enrolled between March 2001 and September 2004. 2.4 Treatment All subjects received interferon alfa-2b (Intron A). …

2020 CIS Annual Meeting: Immune Deficiency & Dysregulation North American Conference.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand.

BackgroundPublic payer reimbursement for non-oncology drugs in Canada, including orphan drugs, is based on recommendations by the Common Drug Review (CDR) (with the exception of Quebec). CDR has been criticized for negative recommendations for orphan drugs and contributing to delays in patient access to these drugs. However, it is unclear how CDR makes recommendations for orphan drugs and the role clinical and economic factors play in decision making. The objective of the present study was to analyze the basis for CDR orphan drug recommendations and to compare recommendations to those in other

Совпадение в полном тексте источника
… Allen et al. [ 53 ] in a comprehensive review of 174 medicine-indication pairs in CDR reports (2009 to 2015) found 78.9%, 81.1% and 78.8% agreement between CDR recommendations and listing decisions in Alberta, British Columbia and Ontario, respectively, for all drugs. … However, analysis of the Allen et al. [ 53 ] data for orphan drugs (22 of the drugs were identified as orphan drugs) indicated only 59.1% and 63.6% agreement with CDR recommendations in Alberta and Ontario, respectively, but 86.4% agreement in British Columbia; only 36.4% of the drugs had the same recommended …

Identifying High-Cost, High-Risk Patients Using Administrative Databases in Tuscany, Italy.

Objective(1) Assessing the performance of the algorithm in terms of sensitivity and positive predictive value, considering General Practitioners' (GPs) judgement as benchmark, and (2) describing adverse events (hospitalisation, death, and health services' consumption) of complex patients compared to the general population.Data sources(i) Tuscany administrative database containing health data (2013-5); (ii) lists of complex patients indicated by GPs; and (iii) annual health registry of Tuscany.Study designThe present study is a validation study. It compares a list of complex patients extracted

Совпадение в полном тексте источника
… Alberta Health Services. Edmonton, Canada: Alberta Health Services; 2009. Medical access to service project—calgary zone, phase 2—outcome assessment—final report. http://www.departmentofmedicine.com/MAS/documents/mas_final_sept1_2009.pdf . …

Lifestyle in Multiple Myeloma - a longitudinal cohort study protocol.

BACKGROUND: Deterioration in bone health is one of the presenting symptoms of Multiple Myeloma (MM), a cancer of plasma cells. As a consequence of this condition, patients suffer bone pain and bone damage and report cancer-related fatigue, resulting in deterioration in their quality of life. Evidence in patients with solid tumours shows promise for the positive effects of physical activity on quality of life. However, in the case of patients with MM a better understanding of the association between physical fitness and quality of life factors is still required. Therefore, this cohort study aim

Совпадение в полном тексте источника
… The Alberta moving beyond breast cancer (AMBER) cohort study: a prospective study of physical activity and health-related fitness in breast cancer survivors. BMC Cancer. 2012;12:525. doi: 10.1186/1471-2407-12-525. 13. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. …

Canadian Society of Nephrology Commentary on the Evolving Kidney Disease Improving Global Outcomes Adult Glomerulonephritis Guidelines.

Purpose of reviewThe purpose of this commentary is to address the challenges of implementing the evolving Kidney Disease Improving Global Outcomes (KDIGO) glomerulonephritis (GN) guidelines within the Canadian health care context, highlighting barriers to adoption of the guidelines and discussing contextual issues unique to Canada.Sources of informationThe KDIGO 2021 guidelines with 2024 updates in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis and lupus nephritis, as well as the 2025 updated guideline for immunoglobulin A (IgA) nephropathy.MethodsA Canadian Society of Nephro

Совпадение в полном тексте источника
… Although a recent cross-sectional study from Alberta noted many adults with CKD would derive both cardiac and renal benefits with SGLT-2i, 11 many did not have access for various reasons, including being of a low socio-economic class. … Use of sodium-glucose cotransporter 2 inhibitors in Alberta adults with chronic kidney disease: a cross-sectional study identifying care gaps to inform knowledge translation. CMAJ Open. 2023;11(1):E101-E109. 12. Pitcher D, Braddon F, Hendry B, et al. Long-term outcomes in IgA nephropathy. …

The future of NMR metabolomics in cancer therapy: towards personalizing treatment and developing targeted drugs?

There has been a recent shift in how cancers are defined, where tumors are no longer simply classified by their tissue origin, but also by their molecular characteristics. Furthermore, personalized medicine has become a popular term and it could start to play an important role in future medical care. However, today, a "one size fits all" approach is still the most common form of cancer treatment. In this mini-review paper, we report on the role of nuclear magnetic resonance (NMR) metabolomics in drug development and in personalized medicine. NMR spectroscopy has successfully been used to evalu

Совпадение в полном тексте источника
… Acknowledgments Research on cancer metabolomics in the author’s laboratory is supported by the Chair in Molecular Cancer Epidemiology, which is funded in turn by the Alberta Cancer Foundation and the Faculty of Medicine. … HJV is currently the holder of a Scientist award from Alberta Innovates Health Solutions. The authors would like to thank Dr. Aru Narendran (Departments of Pediatrics and Oncology, University of Calgary) for providing useful comments on the manuscript. …

Quality of End-of-Life Care in Gastrointestinal Cancers: A 13-Year Population-Based Retrospective Analysis in Ontario, Canada.

Population-based quality indicators of either aggressive or supportive care at end of life (EOL), especially when specific to a cancer type, help to inform quality improvement efforts. This is a population-based, retrospective cohort study of gastrointestinal (GI) cancer decedents in Ontario from 1 January 2006-31 December 2018, using administrative data. Quality indices included hospitalizations, emergency department (ED) use, intensive care unit admissions, receipt of chemotherapy, physician house call, and palliative home care in the last 14-30 days of life. Previously defined aggregate mea

Совпадение в полном тексте источника
… Aggressiveness of End-of-Life Care for Patients With Colorectal Cancer in Alberta, Canada: 2006–2009 J. Pain Symptom Manag. 2014 47 231 244 10.1016/j.jpainsymman.2013.03.021 23870414 9. Jang R.W. Krzyzanowska M.K. Zimmermann C. Taback N. Alibhai S.M.H. …

Use of complementary and alternative medicine by patients with hematological diseases experience at a university hospital in northeast Mexico.

BackgroundComplementary and alternative medicine includes a diverse group of medical and healthcare systems, practices and products not considered part of conventional medicine. Although there is information on unconventional practices in oncological diseases, specific data regarding the use of complementary and alternative medicine by hematology patients is scarce.ObjectiveThe aim of this study is to document the prevalence of this modality of unconventional therapy in patients with malignant and benign hematological diseases, particularly children with acute lymphoblastic leukemia.MethodsAn

Совпадение в полном тексте источника
… J Clin Oncol . 2005 ; 23 ( 12 ): 2645 - 54 Comment in: J Clin Oncol. 2005;23(12):2590-2 15728227 10.1200/JCO.2005.04.126 16 Tough SC Johnston DW Verhoef MJ Arthur K Bryant H Complementary and alternative medicine use among colorectal cancer patients in Alberta, Canada . …

Рекомендации Международной группы по работе с миеломой по диагностике и лечению изолированных плазмоклеточных опухолей.

Одиночные плазмоклеточные опухоли (СП) — редкие локализованные опухоли клоновых плазмоклеток, либо в костной ткани (одиночная костная плазмоклеточная опухоль), либо в мягких тканях/экстраоссозных (экстромедуллярные) с отсутствием или минимальным проникновением в костный мозг (КМ) (<10% клоновых плазмоклеток по иммуногистохимии) и отсутствием признаков системного вовлечения или событий, определяющих миелому. Приблизительно 50% СП прогрессируют в симптоматическую миелому в течение 5 лет после начальной определенной локальной радиотерапии. Увеличение доступности улучшенных диагностических и монит

Совпадение в полном тексте источника
… Paola Neri, University of Calgary: Arnie Charbonneau Cancer Institute, Alberta, Canada 245. Ruben Niesvizky, Weill Cornell Medicine, New York, NY 246. Ajay Nooka, Winship Cancer Institute of Emory University, Atlanta, GA 247. Hanne Norseth, Oslo University Hospital, Oslo, Norway 248. … Linda Pilarski, University of Alberta, Alberta, Canada 272. Romanos Pistofidis, City of Hope, Duarte, CA 273. Rashesh Popat, University College London Hospitals NHS Foundation Trust, London, England, United Kingdom 274. Raymond Powles, Cancer Centre London, London, England, United Kingdom 275. …

Доклад по делу Ига-Ига-И типа Мильомы, совпадающей с Гиперлипидемией.

В большинстве случаев у пациентов с множественной миеломой (ММ) обычно наблюдаются нормальные или пониженные уровни липидов крови. Однако небольшое число случаев свидетельствует о значительной роли белка M в повышенных липидовых уровнях, особенно в тесной связи между типом IgA MM и гипертриглицеридемией и гиперхлестеролемией. Здесь мы сообщаем о случае MM типа Ига-Ига с одновременно гиперлипидемией, когда пациент с повышенным уровнем липидов при поступлении: полный холестерин 10.44 mmol/L (обычный диапазон: 2.8-5.6 mmol/L) и триглицериды 28.45 mmol/L (обычный диапазон: 0.45-1.70 mmol/L) Пациен

Совпадение в полном тексте источника
… J., Alberta L., Robinson‐Bostom L., and Bostom A., “Type III Hyperlipoproteinemia With Xanthomas and Multiple Myeloma,” Journal of the American Academy of Dermatology 53, no. 5 Suppl 1 (2005): S281–S284. 16. Ham J. Y., Suh J. S., Lee W. K., and Song K. …

Презентация и результаты лечения пациентов с множественной миеломой (ММ), опыт работы в едином центре Регионального центра борьбы с раком Виндзора Эссекса.

Результаты для пациентов с множественными миеломами за последние годы значительно улучшились. Это в основном связано с использованием новых агентов. 139 Пациенты с множественной миеломой в региональном онкологическом центре Виндзор Эссекс от Яна. 1, 2015 до Дек. 31, 2019. Средний возраст 71 в течение многих лет и большинство пациентов имели более высокий риск заболевания (65.5% либо на этапе II или III МКС). 30% для миэломы, включая дель 17P, t (FISH для миэломы).4::14), t (14::16) и прибыль (1q21). С точки зрения представления, 38.8% У него была анемия (гемоглобинские результаты почти все)92%

Совпадение в полном тексте источника
… However, the outcome is inferior to those centres that used dual novel agents with or without monoclonal antibody. 6 , 7 A retrospective study from Alberta multiple myeloma registry on 147 patients with median age of 73 years showed median overall survival of 3.3 years for those on CyBorD regimen, which …

Improving rates of pneumococcal vaccination on discharge from a tertiary center medical teaching unit: a prospective intervention.

BackgroundPneumococcal disease causes significant morbidity and mortality in at-risk individuals, and is complicated by emerging antibiotic resistance. An effective, safe and cost-effective vaccine is available, but despite this many patients who would benefit from pneumococcal vaccination remain unvaccinated. The purpose of this study was to determine the rates of missed opportunities to provide pneumococcal vaccination to patients being discharged from a tertiary center medical teaching unit and to determine if a nurse coordinator-based intervention would increase rates of pneumococcal vacci

Совпадение в полном тексте источника
… The National Centre for Streptococcus in Edmonton, Alberta now has reported 10.2% of isolates have diminished susceptibility to penicillin [ 2 ]. Macrolide resistance among invasive S. pneumoniae isolates also dramatically increasing [ 3 ]. …

Abstract

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

N-3 Long-Chain Polyunsaturated Fatty Acids, Eicosapentaenoic and Docosahexaenoic Acid, and the Role of Supplementation during Cancer Treatment: A Scoping Review of Current Clinical Evidence.

This scoping review examines the evidence for n-3 long-chain polyunsaturated fatty acid [LCPUFA, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)] supplementation in clinical cancer therapy. A comprehensive literature search was performed to identify relevant clinical intervention studies conducted through August 2020. Fifty-seven unique cancer trials, assessing EPA and/or DHA supplementation pre- or post-treatment, concomitant with neoadjuvant chemotherapy, radiation or surgery, or in palliative therapy were included. Breast, head and neck, gastrointestinal, gastric, colorectal/rect

Совпадение в полном тексте источника
… Funding This research was funded by Canadian Institute of Health Sciences (CIHR) grant number RES0037745 and the Alberta Canola Producers Commission. Marnie Newell received a studentship from the Alberta Cancer Foundation. Institutional Review Board Statement Not applicable. …

Estimating the Cost of Cancer Care in British Columbia and Ontario: A Canadian Inter-Provincial Comparison.

BackgroundCosting studies are useful to measure the economic burden of cancer. Comparing costs between healthcare systems can inform evaluation, development or modification of cancer care policies.ObjectivesTo estimate and compare cancer costs in British Columbia and Ontario from the payers' perspectives.MethodsUsing linked cancer registry and administrative data, and standardized costing methodology and analyses, we estimated costs for 21 cancer sites by phase of care to determine potential differences between provinces.ResultsOverall, costs were higher in Ontario. Costs were highest in the i

Совпадение в полном тексте источника
… Thus far, work has been done in individual provinces, such as British Columbia (BC) ( Pataky et al. 2016 ), Alberta ( Fassbender et al. 2009 ) and Ontario ( Krahn et al. 2010 ; Mittmann et al. 2012 , 2014 ), examining utilization and costs for individual cancer sites and/or single phases of care. …

Более широкое использование медицинских услуг до начала педиатрического склероза: общенациональное когортное исследование.

Доказательства более широкого использования медицинских услуг до появления многочисленных склерозов у детей говорят о продромальной фазе. Однако мало что известно о его продолжительности или особенностях, и лишь немногие исследования получили доступ к клинической когорте для изучения периода до возникновения симптомов. Мы сравнили годовые показатели использования медицинских услуг до того, как педиатрический множественный склероз наступает в клинических и административных когортах, с соответствующими немногообразными когортами склероза. Мы идентифицировали лиц с педиатрическим множественным ск

Совпадение в полном тексте источника
… Ali Manouchehrinia, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm 171 77, Sweden; Alberta Health Services, Calgary, Canada T5J 3E4. Feng Zhu, Faculty of Medicine (Neurology), University of British Columbia, Vancouver, Canada V6T 2B5. …

Amyloidosis and Carpal Tunnel Syndrome: Surgical Technique for Extended Carpal Tunnel Release with Tenosynovium and Transverse Carpal Ligament Biopsies.

UNLABELLED: Carpal tunnel syndrome (CTS) is common in patients with transthyretin amyloidosis (ATTR), and many experience residual symptoms and/or develop recurrent disease following routine carpal tunnel release (CTR). An extended CTR with median nerve neurolysis is recommended for thorough nerve decompression. Tissue confirmation of amyloidosis can be performed at the time of CTR with biopsies of the transverse carpal ligament and/or tenosynovium. METHODS: We describe a retrospective, single-center experience performing an extended CTR technique including unilateral and bilateral cases for

Совпадение в полном тексте источника
… In recognition of the complex needs of patients with this multisystem disease, amyloidosis patient care is delivered by a multidisciplinary team of clinical specialists that form the Amyloidosis Program of Calgary (APC, University of Calgary, Calgary, Alberta, Canada). …

Биполярное расстройство у людей с множественным склерозом: обновленный систематический обзор и метаанализ.

Множественный склероз (MS) — аутоиммунное расстройство, характеризующееся провокационным демиэлированием внутри центральной нервной системы. Она является второй причиной тяжелой инвалидности и низкого качества жизни среди молодежи. Предыдущие исследования свидетельствуют о значительных различиях в распространенности и риске биполярного расстройства (БД) среди людей, имеющих МЗС, что свидетельствует о необходимости проведения всеобъемлющего анализа для получения надежных оценок. В рамках этого обзора было предложено изучить общую распространенность БД в ПВМС и взаимосвязь между БД и МЗ. МЕТОДЫ:

Совпадение в полном тексте источника
… Gerber B The impact of treatment adherence on clinical and economic outcomes in multiple sclerosis: real world evidence from Alberta, Canada Multiple Scler Relat Disorders 2017 18 218 24 10.1016/j.msard.2017.10.001 29141814 Gerber B, et al. … The impact of treatment adherence on clinical and economic outcomes in multiple sclerosis: real world evidence from Alberta, Canada. Multiple Scler Relat Disorders. 2017;18:218–24. 10.1016/j.msard.2017.10.001 29141814 35. Marrie RA, et al. …

Cancer care treatment attrition in adults: Measurement approaches and inequities in patient dropout rates - a rapid review.

BackgroundCancer treatment attrition refers to the discontinuation of prescribed cancer therapies before completion. It can significantly impact patient outcomes and cancer survival rates making it a critical concern. There is growing evidence on inequalities in cancer care, the avoidable systematic differences in the health of different groups of people. Understanding the extent of treatment attrition, why it happens, for whom, and associated inequalities may improve cancer care delivery and patient outcomes.MethodsA rapid review was conducted to identify existing evidence on measures of canc

Совпадение в полном тексте источника
… Jimenez-Zepeda VH Chen G Shaw E Farris MS Cowling T Tay J Real-world treatment patterns for patients with newly diagnosed multiple myeloma in Alberta, Canada Leuk Lymphoma 2022 63 11 2557 64 10.1080/10428194.2022.2092852 35793400 Jimenez-Zepeda VH, Chen G, Shaw E, Farris MS, Cowling T, Tay J. … Real-world treatment patterns for patients with newly diagnosed multiple myeloma in Alberta, Canada. Leuk Lymphoma. 2022;63(11):2557–64. 35793400 10.1080/10428194.2022.2092852 22. …